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Abstract
Background: Distraction osteogenesis (DO) is one of the most dramatic reconstructive techniques for inducing bone
regeneration, but it involves an undesirably long period for bone consolidation. Developing innovative approaches to
enhance bone consolidation is a burning need. Human fetal mesenchymal stem cells (hFMSCs) have been shown to
express more primitive developmental genes than those of human adult mesenchymal stem cells (hAMSCs), which is a
preferable source for cell therapy and tissue regeneration. In the present study, we investigated the immunogenicity of
using the human mesenchymal stem cell (MSC) secretome on rat cells, the effects of secretome on osteogenic
differentiation of rat bone marrow-derived MSCs (rBMSCs), and the potential application of hFMSC secretome in
promoting bone consolidation in a rat DO model.
Methods: Secretome was collected from MSC culture and was used to treat rBMSCs. Following secretome treatment,
cell proliferation, alkaline phosphatase staining, Alizarin Red S staining, and mRNA expression of osteogenic
differentiation-related genes (including ALP, Runx2, OCN, OPN, and Osx) in the rBMSCs were checked, as well as
mixed rat peripheral blood lymphocyte reaction. hFMSC secretome was injected locally into the regenerates from the
end of lengthening every 3 days in the rat DO model, until termination. The regenerates were subject to weekly x-rays,
micro-computed tomography (μCT) and mechanical testing examination. The bone quality was assessed by histology
and immunohistochemistry examinations.
Results: Compared to the secretome from rBMSCs and hAMSCs, hFMSC secretome had the best osteogenic induction
ability and low immunogenicity. hFMSC secretome with different doses showed no effect on cell viability. hFMSC
secretome at the dose of 100 μg/μl could significantly increase the expression of alkaline phosphatase and all the
osteogenic marker genes, as well as the amount of calcium deposits in the rBMSCs. Finally, the local application of
hFMSC secretome in distraction regenerates in a rat DO model significantly improved bone consolidation according to
the results of μCT, mechanical test, and histological and immunohistochemistry analysis.
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Conclusions: The current study demonstrated that hFMSC secretome promotes osteogenesis of rBMSCs and bone
consolidation during DO. hFMSC secretome may be a new therapeutic strategy to enhance bone consolidation in
patients undergoing DO treatment.
Keywords: hFMSCs, Secretome, Osteogenesis, Distraction osteogenesis, Bone consolidation
Abbreviations: 3D, Three dimensional; ALP, Alkaline phosphatase; BFR/BS, Bone formation rate per unit of bone surface;
BFR/BV, Bone formation rate of bone volume; BFR/TV, Bone formation rate of tissue volume; BV/TV, Bone volume/total
tissue volume; CPC, Cetylpyridinium chloride; dL.S, Double-labeled surface; DO, Distraction osteogenesis; E-modulus, The
modulus of elasticity; FBS, Fetal bovine serum; GAPDH, Glyceraldehyde-3-phosphate dehydrogenase; hAMSCs, Human
adult MSCs; hFMSCs, Human fetal MSCs; MAR, Mineral apposition rate; MS/BS, Ratio of mineralizing surface to bone
surface; MSCs, Mesenchymal stem cells; OCN, Osteocalcin; OIM, Osteogenic induction medium; OPN, Osteopontin;
Osx, Osterix; PBS, Phosphate-buffered solution; rBMSCs, Rat bone marrow-derived MSCs; Runx2, Runt-related transcription
factor 2; SD, Sprague-Dawley; sL.S, Singled labeled surface; VEGF, Vascular endothelial growth factor; α-MEM, Modified
Eagle’s medium of Alpha; μCT, Micro-computed tomography
Background
Distraction osteogenesis (DO) is a dramatic reconstruct-
ive technique that promotes bone regeneration by apply-
ing controlled gradual traction between the osteotomy
cuts. The DO procedure that was first described by
Ilizarov [1], with specific rate and rhythm, could correct
a variety of orthopedic deformities and malformations
with remarkable results [2]. “Tension-stress principle” is
the biological basis for regenerating large segments of
bone that have been lost due to congenital deformity,
trauma, or chronic osteomyelitis [2, 3]. Nevertheless,
despite its widespread application in the clinic, patients
undergoing DO procedure with bulk external fixator
must endure an undesirably long treatment period to
allow bone consolidation. Therefore, innovative ap-
proaches to enhance bone consolidation are in burning
need [4].
Various adult mesenchymal stem cells (MSCs) and
their derivatives have been transplanted into the dam-
aged area to promote tissue repair in both humans and
animals [5, 6]. Because of the poor differentiation and
survival rates after MSC transplantation, the engrafted
MSCs promote tissue regeneration mainly through para-
crine effects [7, 8]. Serum-free conditioned medium de-
rived from human adult MSCs (hAMSCs) was applied
to accelerate bone formation in preclinical animal
models [9]. Moreover, human fetal MSCs (hFMSCs)
have been demonstrated recently to have growth pro-
moting potential; express more primitive developmental
genes, which are preferable for cell therapy and tissue
regeneration [10–12]. hFMSCs have superior cell prolif-
eration capacity, more robust osteogenic potential, and
lower immunogenicity, compared to hAMSCs [13].
The spectrum of regulatory and trophic factors se-
creted by stem cells including growth factors, cytokines,
exosomes, and microRNAs is broadly defined as the
secretome [14]. Stem cells, such as MSCs, are attracted
to the damaged tissue site where they produce the secre-
tome that enhances angiogenesis, reduces inflammation,
promotes tissue repair, and inhibits fibrosis and cell
apoptosis [15–17]. Application of cell-free secretome
could avoid the limitations associated with cell therapy,
such as immune incompatibility, longer waiting time,
and higher costs for cell preparation [18, 19].
In this study, we introduce a method of generating
secretome from MSCs and investigate their effects on
osteogenic differentiation of rat bone marrow-derived
MSCs (rBMSCs) and the effects of local administra-
tion of hFMSC secretome on bone consolidation in a
rat DO model. As an alternative to cell therapy, we
hypothesize that such cell-free secretome from
hFMSCs may have the similar regenerative potential
to enhance bone consolidation in patients undergoing
DO treatment.
Methods
Cell culture and secretome preparation
The bone marrow MSCs were isolated as previously de-
scribed [19, 20]. Briefly, cells were cultured in modified
Eagle’s medium of Alpha (α-MEM; Invitrogen, USA)
supplemented with 10 % fetal bovine serum (FBS; Gibco,
USA) and 1 % penicillin/streptomycin (Gibco, USA) at
37 °C with 5 % CO2 and 95 % humidity. The MSCs from
passages 3–6 were used in the experiments. Meanwhile,
when MSCs reached 80 % confluence they were placed
in serum-free α-MEM, which was used as the positive
control in the animal studies, and incubated for 24 h in
5 % CO2 in a humidified condition, after which the con-
ditioned medium was collected and centrifuged to purify
for 10 min at 4 °C, 4000 g. Then 15 ml conditioned
medium was re-centrifuged with Amicon Ultra Centrifu-
gal Filters (Millipore, USA) for 60 min at 4 °C, 4000 g.
Around 300–400 μl supernatant solution could be col-
lected as cell-free secretome each time. For in vitro
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experiments, 100 μl secretome was added into 3 ml
osteogenic induction medium (OIM), while for in vivo
studies 100 μl secretome was locally injected to the re-
generate zone. The protein content was measured using
the BCSA kit (Thermo Scientific, Rockford, IL, USA) ac-
cording to the manufacturer’s instruction. The concen-
trations of secretome used in vitro and vivo were
100 μg/μl and 3 mg/μl, respectively.
Cell viability assay
The rBMSCs were trypsinized and placed in a flat-
bottomed 96-well plate at an initial density of 5000 cells
per well. After 24 h of incubation, the medium was
changed to hFMSC secretome containing medium at dif-
ferent doses (0, 10 μg/μl, 25 μg/μl, 50 μg/μl, 100 μg/μl,
200 μg/μl). Cells were incubated at 37 °C for 48 and
72 h. The proliferation was determined by methyl thia-
zolyl tetrazolium (MTT) reduction assay. After incuba-
tion, rBMSCs were treated using the MTT solution with
a final concentration of 0.5 mg/ml for 4 h at 37 °C. The
dark blue formazan crystals formed in intact cells were
solubilized with 150 μl DMSO and the plate was shaken
for 10 min. The absorbance was measured at 570 nm
with a microplate reader.
Osteogenic differentiation of rBMSCs
Osteogenic differentiation induction was performed as
previously described [21]. Briefly, the rBMSCs were tryp-
sinized and placed in a 12-well plate at an initial density
of 5000 cells/cm2. When over 80 % confluence was
reached, the medium was replaced with osteogenic in-
duction medium (OIM) including 1 nM dexamethasone,
50 μM L-ascorbic acid-2-phosphate and 20 mM β-glyc-
erophosphate. The osteogenic differentiation was evalu-
ated by alkaline phosphatase (ALP) staining at day 3,
Alizarin Red S staining at days 7 and 14, and quantita-
tive real-time PCR examination of various osteogenic
marker genes at days 3 and 10. Triplicate tests were con-
ducted in each experiment.
ALP staining
After rBMSCs were treated with different kinds of
secretome from rBMSCs, hFMSCs, and hAMSCs, as
well as different doses of hFMSC secretome (0, 10 μg/
μl, 25 μg/μl, 50 μg/μl, 100 μg/μl, and 200 μg/μl) for
3 days, the cells were washed with phosphate-buffered
solution (PBS) twice and fixed with 70 % ethanol for
10 min. The cells were equilibrated by ALP buffer
(0.1 M NaCl, 0.1 M Tris-HCl, 50 mM MgCl2.6H2O,
pH 9.5) for 5 min twice, and incubated with ALP sub-
strate solution (5 μl BCIP and 10 μl NBT in l ml ALP
buffer) at 37 °C in the dark for 60 min, after which the
reaction was stopped with distilled water and the plate
was dried before taking photos.
Alizarin Red S staining
Alizarin Red S staining was performed to evaluate cal-
cium deposit formation. After 7 days of osteogenic in-
duction with different kinds of secretome (100 μg/μl)
from rBMSCs, hFMSCs, and hAMSCs, and 7 and 14 days
with different doses of hFMSC secretome (0, 10 μg/μl,
25 μg/μl, 50 μg/μl, 100 μg/μl, and 200 μg/μl), rBMSCs
were washed with PBS and fixed with 70 % ethanol for
10 min, then the cells were stained with Alizarin Red S
(pH 4.2) for 10 min at room temperature and washed
three times with distilled water. To qualify the
mineralization, the monolayer was eluted with 10 %
cetylpyridinium chloride (CPC; Sigma), and the absorb-
ance was measured at 570 nm.
RNA extraction and quantitative real-time PCR
After rBMSCs were treated with hFMSC secretome at a
dose of 100 μg/μl for 3 and 10 days, total cellular RNA
was extracted with RNA Mini Kit (Invitrogen), and re-
versely transcribed into cDNA with M-MLV reverse
transcriptase (Invitrogen) according to the manufac-
turer’s instructions. Real-time PCR was performed using
the Step One Plus Real-Time PCR System (Applied Bio-
systems, USA). The reaction conditions consisted of
10 μl reaction volumes with diluted cDNA template
1 μl, 5 μl SYBR-Green Master Mix (2×), 3.4 μl PCR-
grade water, and 0.6 μl of each primer (10 μM). The
amplification procedure was carried out as follows: first
at 95 °C for 5 min, and then 40 cycles of 95 °C for 15 s
and 60 °C for 60 s. Primer sequences were as follows:
glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
forward: 5′GGCATGGACTGTGGTCATGAG3′, reverse:
5′TGCACCACCAACTGTTAGC3′; ALP forward: 5′
ACCATTCCCACGTCTTCACATTT3′, reverse: 5′AGAC
ATTCTCTCGTTCACCGCC3′; Runt-related transcrip-
tion factor 2 (Runx2) forward: 5′ACTTCCTGTGC
TCGGTGCT3′, reverse: 5′GACGGTTATGGTCAAGGT
GAA3′; osteocalcin (OCN) forward: 5′CCTCACAC
TCCTCGCCCTATT3′, reverse: 5′CCCTCCTGCTTGG
ACACAAA3′; osteopontin (OPN) forward: 5′GTACCCT
GATGCTACAGACG3′, reverse: 5′TTCATAACTGTCC
TTCCCAC3′; Osterix (Osx) forward: 5′CCAGGCAA
CACTCCTACTCC3′, reverse: 5′GCCTTGCCATACA
CCTTGC3′. The relative quantification of gene expres-
sion was analyzed with the values of 2–ΔΔCT, normalized
with GAPDH expression level.
Mixed rat peripheral blood lymphocyte reaction
For the mixed rat peripheral blood lymphocyte reaction,
1 × 105 peripheral blood lymphocytes (rPBLs) isolated
from healthy rats were added into 100 μl α-MEM and
plated on each well in 96-well plates. After 4 h of cul-
ture, different doses (0, 50 μg/μl, 100 μg/μl, and 200 μg/
μl) of hFMSC secretome and hAMSC secetome in
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100 μl α-MEM were added into each well. rPBSL culture
with serum-free α-MEM served as the baseline control.
After an additional 1, 3, and 5 days of culture, the prolif-
eration of rPBLs was determined by bromodeoxyuridine
(BrdU) incorporation assay according to the manufac-
turer’s manual (Cell Signaling Technology, USA). Op-
tical density was measured at 450 nm.
Animal surgery and distraction osteogenesis protocol
Twenty-four 12-week-old SD male rats were used in our
study. Before surgery, each rat was anesthetized with a so-
lution of 0.2 % (vol/vol) xylazine and 1 % (vol/vol) keta-
mine in PBS. All animals were subjected to a right tibia
transverse osteotomy procedure with a closed fracture at
the midshaft near the fibula-tibia junction under sterile
condition. Of note, the periosteum of the tibia should be
retained as much as possible. A monolateral external dis-
traction fixator (Tianjing Xinzhong Company, China) was
placed to fix proximal and distal segments of the osteot-
omy site. Surgical incisions were then sutured sequentially.
All rats were randomized equally into three groups with
the following treatments: PBS group (n = 8); medium
group (n = 8) and secretome group (n = 8).
The distraction protocol consisted of three phases: a
latency phase of 5 days; a 10-day active lengthening
phase (1 mm/day, in two steps, every 12 h); and a con-
solidation phase of 6 weeks. From the beginning of the
consolidation phase, three groups received injection of
PBS (100 μl), serum-free α-MEM (100 μl), and secre-
tome (100 μl), respectively, into the distraction gap every
3 days until termination. All rats received subcutaneous
injection of calcein (10 mg/kg; Sigma-Aldrich, St. Louis,
MO, USA) at the beginning of the consolidation phase,
and xylenol orange (30 mg/kg, Sigma-Aldrich) 3 days
before termination (day 57 after surgery). Bilateral tibias
were harvested, strapped free of muscle, and processed
for further examinations.
Digital radiographs
At the end of lengthening, a weekly anterior-posterior x-
ray including the distraction zone was taken until ter-
mination using a digital x-ray machine (MX-20, Faxitron
X-Ray Corp., Wheeling, IL, USA) under an exposure
time of 6000 ms and a voltage of 32 kv.
Micro-computed tomography (μCT)
The structural change within the distraction zone in the
rat DO model was quantitatively assessed with μCT as
previously described [22]. Briefly, all the specimens were
imaged using a high-solution μCT (μCT40, Scanco Med-
ical, Bassersdorf, Switzerland) at a custom isotropic
resolution of 8 μm isometric voxel size with a voltage
of 70 kV and a current of 114 μA. Three dimensional
(3D) reconstructions of the mineralized callus were
performed using a global threshold (165 mg hydroxyapa-
tite/cm3), and a Gaussian filter (sigma = 0.8, support = 2)
was applied to suppress noise. Sagittal images of the dis-
traction zone were used to perform 3D histomorpho-
metric analysis. The region of interest was defined as the
distraction zone (regenerate) between the two closest
proximal and distal half-pins. Low- and high-density
mineralized tissues were reconstructed using different
thresholds (low attenuation = 158, high attenuation =
211) using our established evaluation protocol with a
small modification [23]. We selected the volume of
interest to cover the distraction zone. The high-density
tissues represented the newly formed highly mineralized
bone, while the low ones represented the newly formed
callus. Bone volume/total tissue volume (BV/TV) of
each specimen was recorded for analysis.
Four-point bending mechanical testing
A mechanical test was performed within 24 h after ter-
mination at room temperature. The contralateral tibia
was tested as an internal control. A four-point bending
device (H25KS; Hounsfield Test Equipment Ltd., UK)
with a 250 N load cell was used to test the tibia to fail-
ure. The tibias were loaded in the anterior-posterior dir-
ection with the inner and outer span of the blades set as
8 and 18 mm, respectively. The long axis of the tibia was
placed perpendicular to the blades during the test [23].
The modulus of elasticity (E-modulus), ultimate load,
and energy to failure were obtained and analyzed with
built-in software (QMAT Professional; Tinius Olsen,
Inc., Horsham, PA, USA). The biomechanical properties
of the new bone were expressed as percentages of the
contralateral intact bone properties.
Histology and immunohistochemistry
All tibias were initially fixed in 10 % formalin for 48 h.
Half of them were followed by decalcification in 10 %
EDTA solution for 3 weeks and embedded into paraffin.
Thin sections (5 μm) were cut by a rotary microtome
(HM 355S, Thermo Fisher Scientific, Inc., Germany) along
the long axis of each tibia in the sagittal plane. After
deparaffinization, immunohistochemistry staining was
performed. The other half of the specimens were managed
by gradient alcohol dehydration, xylene defatting, and
undecalcification embedded in methyl methacrylate. Thin
(5 μm) and thick (10 μm) sections were cut with the
RM2155 hard tissue microtome (Leica, Wetzlar, Germany)
along the long axis of the tibia, respectively. The 5-μm
sections were stained with Trichrome Goldner and Von
Kossa for static histomorphometric analysis, while the un-
stained 10-μm ones were used for dynamic histomorpho-
metric measurements, which contained singled labeled
surface (sL.S), double-labeled surface (dL.S), ratio of min-
eralizing surface to bone surface (MS/BS, calculated as
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double plus half of single-labeled surfaces (sL.S)), mineral
apposition rate (MAR), bone formation rate per unit of
bone surface (BFR/BS), bone formation rate of bone vol-
ume (BFR/BV), and bone formation rate of tissue volume
(BFR/TV).
Immunohistochemistry staining was performed using
a standard protocol as previously reported [24]. Secre-
tions were treated with primary antibodies to rabbit
osterix (Osx; Abcam, 1:100, ab22552) and osteocalcin
(OCN; Santa Cruz, 1:100, sc30045) overnight at 4 °C; a
horseradish peroxidase-streptavidin detection system
(Dako, USA) was used, followed by counterstaining with
hematoxylin. The positive stained cell numbers in the
whole distraction zone per specimen in three sequential
sections (50 μm, 150 μm, and 250 μm) per rat in each
group were counted and compared, and were expressed
as the percentages of the bone volume.
Statistical analysis
All quantitative data were analyzed using SPSS 18.0 soft-
ware for windows (SPSS, Chicago, IL, USA). Non-
parametric test was used for comparison of mean values
with p < 0.05 considered as statistically significant.
Results
Effect of different kinds of secretome on osteogenic
differentiation of rBMSCs
To compare the osteogenic effects of rBMSC secretome,
hFMSC secretome, and hAMSC secretome on the osteo-
genic differentiation of rBMSCs, ALP and Alizarin Red S
staining were performed. The results showed that both
rat and human secretome could induce osteogenic dif-
ferentiation of rBMSCs. Furthermore, the hFMSC secre-
tome demonstrated the strongest osteogenic induction
ability (Fig. 1a, b).
Immunogenicity of secretome from hFMSCs and hAMSCs
The responses of rat peripheral blood lymphocyte cul-
ture treated with hFMSC secretome and hAMSC secre-
tome were tested by mixed lymphocyte reaction. The
results showed a dramatic lymphocyte proliferation
under hAMSC secretome treatment in a concentration
-dependent manner at days 1 and 3. At day 5, the low
BrdU incorporation indicated cells might reach the sta-
tionary phase (Fig. 1d). In contrast, the hFMSC secre-
tome treatment at all the tested concentrations did not
induce significant lymphocyte proliferation (Fig. 1c).
Fig. 1 Secretome from human fetal mesenchymal stem cells (hFMSCs) had more osteogenic potential and lower immunogenicity than that from
rat bone marrow-derived mesenchymal stem cells (rBMSCs) and human adult mesenchymal stem cells (hAMSCs), as well as no effect on cell viability.
a Both the alkaline phosphatase (ALP) staining and Alizarin Red S staining showed that more calcium deposits could be found after hFMSC secretome
treatment. b The semi-quantitative results of Alizarin Red S staining demonstrated that significantly more mineralization was seen in the hFMSC
secretome group. c Immunogenicity was determined by mixed rat peripheral blood lymphocyte reaction. The hFMSC secretome had no significant
effect on rat peripheral blood lymphocyte proliferation. d Significant lymphocyte proliferation was stimulated after administration of hAMSC secretome.
e Cell viability was evaluated by the MTT assay. The optical density (OD) level of rBMSCs treated with hFMSC secretome showed no significant
difference among the doses from 10 μg/μl to 200 μg/μl. *p < 0.05, **p < 0.01. d days
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Different doses of hFMSC secretome had no effect on cell
viability but promoted osteogenic differentiation of rBMSCs
To investigate the effect of hFMSC secretome on cell viabil-
ity, the MTT assay was performed. The results showed that
there was no significant difference among the five groups
with different doses of secretome (excluding the dose of 0)
during 48- and 72-h culture (Fig. 1e). To clarify the effect
of different doses of hFMSC secretome on osteogenesis of
rBMSCs in vitro, ALP and Alizarin Red S staining were per-
formed at day 3, and days 7 and 14, respectively. The ex-
pression of alkaline phosphatase and the amount of
calcium deposits were remarkably increased in the group
with a dose of 100 μg/μl. The quantitative results showed
that hFMSC secretome at a dose of 100 μg/μl could signifi-
cantly increase calcium nodule formation compared to
other doses (Fig. 2). Furthermore, the real time PCR results
demonstrated a remarkable increase in the expression of
Runx2, OCN, OPN, and Osx in the secretome group with
the dose of 100 μg/μl at days 3 and 10. The ALP in the
secretome group was significantly upregulated at day 3, but
showed no significant difference at day 10 (Fig. 3).
Radiographic assessment of the distraction zone
Representative series of x-rays across the time-course of
DO showed the progression of bone consolidation
(Fig. 4). Little callus was observed in the gap at the end
of distraction in all groups. However, as time went on,
more callus formation was found in the secretome treat-
ment group compared to the medium group and PBS
group until termination. A similar result was found in
the 6-week images using μCT (Fig. 5a). The value of BV/
TV at week 6 indicated that more newly formed miner-
alized bone was detected in the secretome treatment
group compared to the other two groups, while there
was no remarkable difference between the medium
group and the PBS group (Fig. 5b).
Mechanical testing
The results of four-point bending mechanical testing in
the secretome treatment group showed a significant im-
provement in ultimate load and energy to failure com-
pared to the other two groups after being normalized
with the contralateral intact tibia. However, there was no
significant difference between the secretome treatment
group and the medium group in E-modulus (Fig. 5c).
Histological analysis
Representative sections from three groups stained with
Trichrome Goldner and Von Kossa are shown in Fig. 6.
More chondrocytes were detected in the PBS group and
Fig. 2 Human fetal mesenchymal stem cell (hFMSC) secretome promoted osteogenic differentiation of rBMSCs in vitro. The alkaline phosphatase
(ALP) staining was conducted after 3 days of treatment with secretome with different doses in OIM, and the Alizarin Red S staining and its
quantitated measurement were performed after 7 and 14 days administration of secretome. Significantly more mineralization was seen in the
hFMSC secretome group with a dose of 100 μg/μl. **p < 0.01. d day, OD optical density
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the medium treatment group than in the secretome
treatment group, suggesting that the newly formed
chondrocytes have not been mineralized completely in
the two groups. In contrast, most of the new bone had
been consolidated and the continuity of the cortical
bone and bone marrow cavities were reconstructed in
the secretome treatment group. Dynamic histomorpho-
metric data are presented in Fig. 7a and b. MS/BS,
MAR, BFR/BS, BFR/BV, and BFR/TV were significantly
increased in the secretome treatment group compared
to the medium group and the PBS group, suggesting that
bone consolidation was enhanced by the secretome
treatment. Osx and OCN immunohistochemistry stain-
ing confirmed more Osx- and OCN-positive cells in the
new bone zone in the secretome treatment group than
in the other two groups (Fig. 8).
Discussion
In the present study, we have introduced a promising ap-
plication of hFMSC secretome therapy, and established
Fig. 3 hFMSC secretome upregulated levels of osteogenic mRNA expression in rBMSCs. Osteogenic marker gene expressions were detected by
quantitative real-time PCR after treatment with secretome at the dose of 100 μg/μl in OIM for 3 and 10 days. *p < 0.05, **p < 0.01, compared with
OIM. ALP alkaline phosphatase, OCN osteocalcin, OPN osteopontin, Osx osterix, Runx2 Runt-related transcription factor 2
Fig. 4 Animal experimental design and representative x-rays of distraction regenerate at various time points. a After a 5-day latency period,
distraction was initiated over 10 days at 1 mm/day in two equal increments. Local injection of PBS, serum-free α-MEM, and secretome started
from the beginning of the consolidation phase, and every 3 days thereafter until termination. b Little callus was seen in the gap immediately after
distraction in three groups, while more continuous callus appeared in the secretome group as time went on, especially at the end of the consolidation
phase, whereas an obvious gap was still seen in the other two groups. d day, hFMSC human fetal mesenchymal stem cell, PBS phosphate-buffered saline
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the positive effect of hFMSC secretome on osteogenic dif-
ferentiation of rBMSCs and the therapeutic potential to
promote bone consolidation in a rat DO model.
MSCs have the ability to differentiate into various spe-
cific cell types and promote tissue regeneration both by
replacing damaged tissues and by trophic and paracrine
mechanisms [6]. Recently, hFMSCs have been demon-
strated to be the most promising cell source for bone
tissue engineering application because of their lower im-
munogenicity, and higher proliferative and osteogenic
capacity compared to hAMSCs [13, 25]. However, the
stem cells have poor differentiation and a poor survival
rate following their transplantation in vivo that has lim-
ited their regenerative potential [26]. Although the pro-
liferative and differentiation capacities of hFMSCs can
be retained and their osteogenic potentials may be en-
hanced through gene modulation [25, 27], the genetic
modification procedure is rather complicated and fur-
ther studies are still needed before their clinical applica-
tion. In contrast, cell-free secretome harvested from the
hFMSC conditioned medium centrifugation is an easy
and cost-effective procedure. To rule out the possible ef-
fects of serum factors, we cultured rBMSCs, hFMSCs,
and hAMSCs in serum-free medium before we collected
Fig. 5 Secretome administration improved the quality of new callus via μCT analysis and mechanical test. a 3D μCT images of the tibia distraction
zone in three groups confirmed more continuous callus was found after secretome treatment. b μCT analysis data showed bone volume/total tissue
volume (BV/TV) of newly consolidated bone in the secretome group was much higher than that in the phosphate-buffered saline (PBS) and medium
groups. Attenuation above 158 represented total mineralized tissue, and attenuation between 158 and 211 represented the new callus. c Better
mechanical properties (including the modulus of elasticity (E-modulus), ultimate load, and energy to failure) of distraction tibia were shown in the
secretome group (%). *p < 0.05, compared with PBS or medium group, n = 8. hFMSC human fetal mesenchymal stem cell
Fig. 6 Histological analysis showed that the secretome intervention accelerated new callus consolidation. a Representative sections stained with
Trichrome Goldner showing better quality callus formation in the secretome group than in the other two groups. b Von Kossa staining clearly
showed that most of the new bone has been consolidated and the continuity of the cortical bone and bone marrow cavities was evident in the
secretome group at week 6. hFMSC human fetal mesenchymal stem cell, PBS phosphate-buffered saline
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the secretome. MSC secretome contains many innate
immunomodulatory and trophic factors that will benefit
tissue repair [14].
In the current study, we showed that all three kinds of
secretome (rBMSCs, hAMSCs, and hFMSCs) promoted
osteogenic differentiation of rBMSCs, and the human
MSC secretome could act similar to or even better than
rat MSC secretome. The hFMSC secretome showed the
strongest osteogenic induction ability. Most interest-
ingly, compared to the hAMSC secretome, the hFMSC
Fig. 7 Dynamic histomorphometric measurements showed more quantitative bone formation in the secretome group. a Arrows point to the
calcein and xylenol orange labeling in representative images of three groups. b Quantitative measurements of dynamic histomorphometric
parameters containing MS/BS, MAR, BFR/BS, BFR/BV, and BFR/TV were significantly increased in the secretome group. **p < 0.01, compared to PBS
group and medium group. BFR/BS bone formation rate per unit of bone surface, BFR/BV bone formation rate of bone volume, BFR/TV bone
formation rate of tissue volume, hFMSC human fetal mesenchymal stem cell, MAR mineral apposition rate, MS/BS ratio of mineralizing surface to
bone surface, PBS phosphate-buffered saline
Fig. 8 Immunohistochemical analysis of the percentages of Osx- and OCN-positive cells in the distraction zone. The secretome treatment has
significantly increased numbers of Osx (A–D) and OCN (a-d) positive cells (brown) compared to the PBS and medium treatment (**p < 0.01).
hFMSC human fetal mesenchymal stem cell, OCN osteocalcin, Osx osterix, PBS phosphate-buffered saline
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secretome did not trigger any significant immune re-
sponse, and hence the potential non-specific response
caused by human protein in rats was disregarded in the
current study using the hFMSC secretome. Furthermore,
hFMSC secretome at different doses did not affect rBMSC
viability or cell proliferation, and the concentration of
100 μg/μl could significantly enhance ALP activity and
formation of calcium nodules during rBMSC osteogenic
induction, indicating enhancement of mineralization [28].
The expression level of some osteogenic marker genes in-
cluding Runx2, OCN, OPN, and Osx were all significantly
upregulated at days 3 and 10 following hFMSC secretome
treatment. ALP can promote mineralization through its
ability for hydrolyzing pyrophosphate and generating inor-
ganic phosphate, and is responsible for osteoblastic differ-
entiation at an early stage, while OCN plays an important
role in the late stage of mineralization [29, 30]. Runx2 is
involved in the production of bone matrix proteins and is
essential for osteoblast differentiation [31]. Expression
levels of OPN can be upregulated by growth and differen-
tiation factors to promote bone formation and remodeling
[32]. Osx, downstream of Runx2, is required for osteoblast
differentiation and bone formation [33]. Taken together,
we confirmed that hFMSC secretome enhanced osteo-
genic differentiation of rBMSCs in vitro. When we admin-
istered hFMSC secretome locally into the DO gap in rats,
new bone formation and consolidation were significantly
accelerated. This was also confirmed by histological ana-
lysis results, including Trichrome Goldner and Von Kossa
staining, and the dynamic histomorphometric data, while
most of the cartilage tissues in the distraction zone in the
PBS group and the medium group remained unconsoli-
dated in the callus. The healing quality of new bone in the
distraction zone was quantified by a mechanical test and
μCT. E-modulus, ultimate load, energy to failure, and BV/
TV all have better results, demonstrating more callus for-
mation and mineralization in the secretome treatment
group.
The DO procedure stimulates the recruitment and
proliferation of bone progenitor cells to the target site,
where they promote angiogenesis and bone formation/
mineralization [6, 34]. Mechanisms as to how hFMSC
secretome augments bone formation and maintains vas-
cularity are still unclear. Recently, Karp and Leng Teo
have demonstrated that the effect of MSC secretome on
tissue repair can be improved through enhancing sur-
vival of the progenitor cells that homed to the target site
[35], whereas the release of vascular endothelial growth
factor (VEGF) was activated by MSC secretome under
hypoxia or normoxia stimulation [36]. The study of
Jacobsen et al. showed that VEGF is highly expressed in
the formation of both bone and blood vessels during
DO and is needed to promote osteogenic differentiation
over chondrogenic differentiation of MSCs [37]. That
might be the reason for more cartilage still remaining in
the PBS group and medium group in our current study.
Moreover, once committed to the osteogenic lineage,
MSCs express Osx and OCN which are markers of
osteoprogenitors [24, 38]. The number of Osx- and
OCN-positive osteoprogenitors was significantly upregu-
lated in the distraction zone after treatment with hFMSC
secretome compared to the control treatment groups. A
wide array of signaling pathways may be involved in
VEGF production following hFMSC secretome treat-
ment, and further research is warranted to verify the
current findings.
Despite our promising findings, there are several limi-
tations in the current study. On the one hand, the effect-
iveness and potential immunogenicity of using human
proteins in rats still need further careful investigation.
Despite our data confirming that hFMSC secretome had
significantly enhanced osteogenic differentiation of
rBMSCs and caused no detectable immunological re-
sponses, their exact mechanisms of action need further
exploration. On the other hand, the microenvironments
in vivo are highly dynamic, and the secretome contents
likely change from what they would be in vitro; it will be
interesting to examine the properties of hFMSC
secretome changes over time or at pre- and post-
transplantation stages. Meanwhile, future research en-
deavors should emphasize developing slow-releasing
methods to maintain sustainability of the secretome
under a dynamically changing microenvironment such
as the regenerates of DO.
Conclusions
In conclusion, our data confirmed that hFMSC secre-
tome improves the osteogenic differentiation potential of
rBMSCs and accelerates bone consolidation during DO
in a rat model. A novel application of hFMSC secretome
is proposed with a clinical potential to enhance bone
consolidation of DO treatment for patients with limb
discrepancy, severe deformities, and bone defects.
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